CHUGAI PHARMACEUTICAL CO LTDCC

CHUGAI PHARMACEUTICAL CO LTD

46.09EURR
−0.20−0.43%
At close at 20:43 GMT
EUR
No trades
See on Supercharts

CUP fundamentals

Key facts

Market capitalization‪77.06 B‬EUR
Founded1925
CEOOsamu Okuda
About

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Ownership
‪‪1.65 B‬‬
Closely held shares
‪‪1.03 B‬‬ (62.73%)
Free Float shares
‪‪613.23 M‬‬ (37.27%)
Closely held shares
‪‪1.03 B‬‬ (62.73%)
Free Float shares
‪‪613.23 M‬‬ (37.27%)
Capital structure
Market cap
‪‪77.06 B‬‬
Cash & equivalents
‪‪6.12 B‬‬
Enterprise value
‪‪70.94 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪77.06 B‬‬
Price to earning ratio (P/E)
31.06x
Price to sales ratio (P/S)
10.27x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
31.06x
Price to sales ratio (P/S)
10.27x
Valuation ratios
‪0.00‬
‪2.50‬
‪5.00‬
‪7.50‬
‪10.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
‪32.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪30.0%‬
‪31.5%‬
‪33.0%‬
‪34.5%‬
‪36.0%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceuticals
Other
By country
Period: 2024
Japan
Switzerland
Overseas

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Actual
Estimate
Earnings
Next:Apr 24, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.11‬
‪0.22‬
‪0.33‬
‪0.44‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
41.63%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
1.32%
Next payment
0.792
Next ex-date
Jun 26, 2025
Dividend history
‪0.95%‬
‪1.35%‬
‪1.75%‬
‪2.15%‬
‪2.55%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.16‬
‪0.32‬
‪0.48‬
‪0.64‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Assets
Liabilities